---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-23-008353"
form_type: "8-K"
ticker: "EDSA"
cik: "0001540159"
company_name: "Edesa Biotech, Inc."
filed_at: "2023-06-23T23:59:59+00:00"
generated_at: "2026-06-13T18:00:00.429436+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Edesa Biotech receives Nasdaq deficiency letter for bid price below $1, has 180 days to cure

## Summary
- Company has until Dec 19, 2023 to regain compliance by closing at $1 or more for 10 consecutive business days.
- If not cured, may qualify for another 180-day period subject to meeting other Nasdaq standards and a reverse split.
- Nasdaq listing remains fully effective; no immediate impact on trading of EDSA common shares.
- Company will monitor bid price and consider options to regain compliance, but cannot assure success.

## SEC filing metadata
- accession: 0001654954-23-008353
- form_type: 8-K
- ticker: EDSA
- cik: 0001540159
- company_name: Edesa Biotech, Inc.
- filed_at: 2023-06-23T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1540159/000165495423008353/0001654954-23-008353-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1540159/000165495423008353/edsa_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-23-008353
- JSON: https://secwatch.observer/filing/0001654954-23-008353.json
- Plain text: https://secwatch.observer/filing/0001654954-23-008353.txt

## Key facts
- Listing & Compliance Notices
  Edesa Biotech, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2), 5810(c)(3)(A)
  source text: June 22, 2023, Edesa Biotech, Inc. (the “Company”) received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, based on the closing bid price of the Company’s common shares, no par value per share (the “Common Shares”), for the last 30 consecutive business days, the Company is not in compliance with the minimum bid price requirement of $1.00 per share for continued listing, as set forth in Nasdaq Listing Rule 5550(a)(2). The Nasdaq notification has no immediate impact on the listing of the Company’s Common Shares on The Nasdaq C
  evidence_url: https://www.sec.gov/Archives/edgar/data/1540159/000165495423008353/0001654954-23-008353-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.